Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04629991 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| first of three dosing cohorts | OTHER | - |
| second of three dosing cohorts | OTHER | - |
| third of three dosing cohorts | OTHER | - |
| Name | Type | Description |
|---|---|---|
| PF-04629991 | DRUG | Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the first cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses) |
Inclusion Criteria: * Healthy non-smoking men and women * body mass index 18-30 kg/m2 Exclusion Criteria: * Women must not be able to have children * no current infections
PF-04629991 is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in Phase 1 clinical development. The drug is being evaluated for safety, tolerability, pharmacokinetics and pharmacodynamics in a clinical trial setting.
PF-04629991 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research on this investigational small molecule drug.
PF-04629991 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to assess its safety, tolerability, pharmacokinetics and pharmacodynamics.
PF-04629991 has one completed Phase 1 clinical trial, identified as NCT00797342. This study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of the drug in 27 healthy volunteers in Belgium. The trial was randomized, double-blind and controlled.
PF-04629991 is a unique investigational compound developed by Pfizer. No alternative names for this drug have been reported in clinical trial registries. It is identified solely by its Pfizer code name PF-04629991 in the completed Phase 1 study.